​

Molecular Partners (MOLN) Stock Forecast, Price Target & Predictions

OverviewChart

MOLN Stock Forecast

Molecular Partners (MOLN) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 192.13% increase from the last price of $4.45.

$3 $5 $7 $9 $11 $13 High: $13 Avg: $13 Low: $13 Last Closed Price: $4.45

MOLN Stock Rating

Molecular Partners stock's rating consensus is Hold, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (25.00%), 3 Hold (75.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 4 0 3 1 Strong Sell Sell Hold Buy Strong Buy

MOLN Price Target Upside V Benchmarks

TypeNameUpside
StockMolecular Partners192.13%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$13.00
Last Closing Price$4.45$4.45$4.45
Upside/Downside--192.13%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26-41--5
Mar, 26-41--5
Feb, 26-41--5
Jan, 26-31--4
Dec, 25-31--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 27, 2026H.C. Wainwright$13.00$4.00225.00%192.13%
Apr 27, 2022Leerink Partners$29.00$13.89108.78%551.69%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 16, 2026Cowen & Co.BuyBuyhold
Jan 27, 2026H.C. WainwrightBuyinitialise
Apr 27, 2022SVB LeerinkOutperformOutperformhold
Apr 27, 2022Credit SuisseNeutraldowngrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.06$3.63$-1.89-----
Avg Forecast$-1.86$3.43$-1.93$-1.80$-2.03$-2.13$-2.82$-2.72
High Forecast$-1.79$3.43$-1.61$-1.61$-1.67$-1.37$-2.82$-2.72
Low Forecast$-1.93$3.43$-2.30$-2.00$-2.46$-2.88$-2.82$-2.72
Surprise %10.75%5.83%-2.07%-----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$9.33M$189.56M$7.04M-----
Avg Forecast$15.35M$180.08M$5.84M$4.60M$2.37M$15.04M$16.15M$28.89M
High Forecast$15.79M$180.08M$6.24M$4.81M$2.37M$15.04M$16.15M$28.89M
Low Forecast$14.90M$180.08M$5.44M$4.38M$2.37M$15.04M$16.15M$28.89M
Surprise %-39.21%5.26%20.51%-----

Net Income Forecast

$-100M $-50M $0 $50M $100M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-63.78M$117.85M$-61.98M-----
Avg Forecast$-61.06M$112.34M$-61.98M$-62.59M$-74.70M$-79.50M$-92.50M$-89.19M
High Forecast$-58.76M$112.34M$-52.89M$-52.87M$-54.61M$-45.01M$-92.50M$-89.19M
Low Forecast$-63.34M$112.34M$-75.23M$-65.40M$-80.48M$-94.38M$-92.50M$-89.19M
Surprise %4.46%4.91%------

MOLN Forecast FAQ

Is Molecular Partners stock a buy?

Molecular Partners stock has a consensus rating of Hold, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Molecular Partners is a neutral investment for most analysts.

What is Molecular Partners's price target?

Molecular Partners's price target, set by 4 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 192.13% change from the previous closing price of $4.45.

How does Molecular Partners stock forecast compare to its benchmarks?

Molecular Partners's stock forecast shows a 192.13% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Molecular Partners over the past three months?

  • April 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Molecular Partners’s EPS forecast?

Molecular Partners's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.8, marking a -4.76% decrease from the reported $-1.89 in 2023. Estimates for the following years are $-2.03 in 2025, $-2.13 in 2026, $-2.82 in 2027, and $-2.72 in 2028.

What is Molecular Partners’s revenue forecast?

Molecular Partners's average annual revenue forecast for its fiscal year ending in December 2024 is $4.6M, reflecting a -34.64% decrease from the reported $7.04M in 2023. The forecast for 2025 is $2.37M, followed by $15.04M for 2026, $16.15M for 2027, and $28.89M for 2028.

What is Molecular Partners’s net income forecast?

Molecular Partners's net income forecast for the fiscal year ending in December 2024 stands at $-62.591M, representing an 0.98% increase from the reported $-61.984M in 2023. Projections indicate $-74.7M in 2025, $-79.5M in 2026, $-92.495M in 2027, and $-89.192M in 2028.